Determination of butyric acid dosage based on clinical and experimental studies - a literature review.
butyrate
dosage
irritable bowel syndrome
short-chain fatty acids
Journal
Przeglad gastroenterologiczny
ISSN: 1895-5770
Titre abrégé: Prz Gastroenterol
Pays: Poland
ID NLM: 101280380
Informations de publication
Date de publication:
2020
2020
Historique:
received:
14
05
2020
accepted:
15
05
2020
entrez:
20
6
2020
pubmed:
20
6
2020
medline:
20
6
2020
Statut:
ppublish
Résumé
Short-chain fatty acids produced by bacteria living in the large intestine are the main energy substrate for the colonocytes. Butyric acid is used for the treatment and prevention of exacerbations of various gastrointestinal diseases: diarrhoea, intestinal inflammations, functional disorders, dysbiosis, and post-surgery or post-chemotherapy conditions. The current standard doses of butyric acid (150-300 mg) range between 1.5-3% and 15-30% of the reported daily demand. Increased metabolism of the colonocytes in conditions involving intestine damage or inflammation, increased energy expenditure during a disease, stimulation of intestine growth in 'stress' conditions with accelerated intestinal passage and increased intestinal excretion, and decreased production of endogenous butyrate due to changes in bacterial flora in different pathological conditions require a significant increase of the supply of this acid. Physiological high demand for butyrate and known mechanisms of pathological conditions indicate that current supplementation doses do not cover the demand and their increase should be considered.
Identifiants
pubmed: 32550943
doi: 10.5114/pg.2020.95556
pii: 40722
pmc: PMC7294979
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
119-125Informations de copyright
Copyright: © 2020 Termedia Sp. z o. o.
Déclaration de conflit d'intérêts
The authors whose names are listed immediately below certify that they have no affiliations with or involvement in any organization or entity with any financial interest, or non-financial interest in the subject matter or materials discussed in this manuscript.
Références
Ann Nutr Metab. 2017;71 Suppl 1:23-30
pubmed: 28950281
Curr Nutr Rep. 2018 Dec;7(4):198-206
pubmed: 30264354
Adv Immunol. 2014;121:91-119
pubmed: 24388214
Clin Epigenetics. 2012 Feb 27;4(1):4
pubmed: 22414433
Proc Nutr Soc. 1996 Nov;55(3):937-43
pubmed: 9004335
mBio. 2019 May 7;10(3):
pubmed: 31064831
Br Poult Sci. 2011 Jun 1;52(3):292-301
pubmed: 21732874
J Surg Res. 2018 Jun;226:64-71
pubmed: 29661290
J Mol Endocrinol. 2020 Jan;64(1):29-42
pubmed: 31770101
Biomedicines. 2019 Sep 24;7(4):
pubmed: 31554278
J Immunol. 2017 Mar 1;198(5):2172-2181
pubmed: 28100682
Travel Med Infect Dis. 2014 Mar-Apr;12(2):183-8
pubmed: 24063909
Gastroenterology. 1997 Oct;113(4):1188-97
pubmed: 9322514
Clin Nutr. 2009 Feb;28(1):88-93
pubmed: 19108937
Br J Nutr. 2014 May 28;111(10):1748-58
pubmed: 24506942
World J Gastroenterol. 2011 Mar 28;17(12):1519-28
pubmed: 21472114
Oncotarget. 2015 Jun 30;6(18):15902-30
pubmed: 26079539
Sci Rep. 2016 Aug 25;6:31917
pubmed: 27558220
PLoS One. 2015 Mar 09;10(3):e0119362
pubmed: 25751150
Anim Sci J. 2019 Jan;90(1):3-13
pubmed: 30370625
Biomed Res Int. 2019 Jul 25;2019:3405278
pubmed: 31428633
Sci Rep. 2019 Jan 28;9(1):775
pubmed: 30692581
Eur J Clin Invest. 2003 Mar;33(3):244-8
pubmed: 12641543
Scand J Gastroenterol Suppl. 1997;222:53-7
pubmed: 9145448
Front Neurol. 2019 Jun 28;10:661
pubmed: 31316450
Gastroenterology. 1991 Dec;101(6):1497-504
pubmed: 1955116
Sci Rep. 2019 Mar 18;9(1):4822
pubmed: 30886210
Clin Nutr. 2020 Jun;39(6):1692-1704
pubmed: 31542246
Aliment Pharmacol Ther. 2005 Nov 1;22(9):789-94
pubmed: 16225487
Obes Rev. 2018 Dec;19 Suppl 1:61-72
pubmed: 30511508
J Periodontal Res. 2019 Oct;54(5):566-571
pubmed: 30982987
Gut. 1980 Sep;21(9):793-8
pubmed: 7429343